Current Month
Article Features
  Breast Cancer Places Greater Financial Burden on Black Women
Diagnosing Breast Cancer with an Imaging Pill
Financial Support and Incentives are Effective at Increasing Physical Activity Among Breast Cancer Survivors
For Young Women at High Genetic Risk of Breast Cancer, Plastic Surgeons Play a Key Role in Treatment
Is Prognosis Poor for Breast Cancer Diagnosed After Negative Screening Mammography?
Making Individualized Choices About Breast Cancer Screening
New Guidelines to Help Clinicians Manage Genitourinary Syndrome of Menopause (GSM) in Women with Breast Cancer
Osteoporosis Drug Could Be Used to Treat Aggressive Form of Breast Cancer
Parenting Concerns Create Challenges for Mothers with Advanced Cancer and Dependent Children
Scientists Identify Cause of Resistance to Breakthrough Breast and Ovarian Cancer Drug
Study Identifies New Potential Treatment Option for Triple-Negative Breast Cancer
Study Links Breast Cancer to the Body’s Internal Clock
Surgery Benefits Older Women with Breast Cancer
Using Telemedicine to Bring Genetic Counseling to Community Cancer Care

Surgery Benefits Older Women with Breast Cancer

In a British Journal of Surgery analysis of 18,730 older patients with estrogen receptor-positive breast cancer in the UK, the risk of dying from breast cancer was greater in patients treated with primary endocrine therapy than in those who received surgery.

For the study, researchers analyzed cancer registration data from two English regions from 2002 to 2010. Only 69 percent of women survived for 5 years if they received only endocrine therapy (anti-estrogen drugs, such as tamoxifen or aromatase inhibitors), compared with 90 percent of women who had surgery.

The study's investigators note that primary endocrine therapy is used in up to 40 percent of women in the UK with early breast cancer over age 70 years.

British Journal of Surgery, May 22, 2018

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon